Abstract
Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1) N-methylates nicotinamide to produce 1-methylnicotinamide (MeN). We have previously shown that NNMT expression protected against neurotoxin-mediated cell death by increasing Complex I (CxI) activity, resulting in increased ATP synthesis. This was mediated via protection of the NDUFS3 subunit of CxI from degradation by increased MeN production. In the present study, we have investigated the effects of NNMT expression on neurone morphology and differentiation. Expression of NNMT in SH-SY5Y human neuroblastoma and N27 rat mesencephalic dopaminergic neurones increased neurite branching, synaptophysin expression and dopamine accumulation and release. siRNA gene silencing of ephrin B2 (EFNB2), and inhibition of Akt phosphorylation using LY294002, demonstrated that their sequential activation was responsible for the increases observed. Incubation of SH-SY5Y with increasing concentrations of MeN also increased neurite branching, suggesting that the effects of NNMT may be mediated by MeN. NNMT had no significant effect on the expression of phenotypic and post-mitotic markers, suggesting that NNMT is not involved in determining phenotypic fate or differentiation status. These results demonstrate that NNMT expression regulates neurone morphology in vitro via the sequential activation of the EFNB2 and Akt cellular signalling pathways.
Similar content being viewed by others
Main
Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1) catalyses the N-methylation of nicotinamide into 1-methylnicotinamide (MeN).1 In the brain, NNMT expression is regionally distributed, occurring solely in neurones.2 NNMT expression is elevated in numerous cancers, for example, bladder, lung and gastrointestinal tract,3, 4, 5 and NNMT may serve as a prognostic marker for these cancers.6, 7 NNMT is hepatoprotective in hepatitis and cirrhosis8 and protects against free radicals in pulmonary smooth muscle cells in chronic obstructive pulmonary disease.9
Using post mortem caudate nucleus and cerebella, we have shown that the expression of NNMT is increased in Parkinson’s disease (PD) brains.2, 10 Stable expression of NNMT in the SH-SY5Y human neuroblastoma cell line, which has no endogenous expression of NNMT, at levels of activity comparable with that in PD brain, protected against the toxicity of the Complex I (CxI) inhibitors 1-methyl-4-phenylpyridinium ion and rotenone.11 This protection was mediated via increased CxI activity and ATP production. Maintenance of CxI activity arose from protection of the 30 kDa subunit of CxI (NDUFS3) from degradation induced by 1-methyl-4-phenylpyridinium ion and rotenone. Thus increased NNMT expression may be a stress response of the neurone to the PD pathogenic process.
Induction of NNMT in renal clear cell carcinoma (RCC) cells activated matrix metalloproteinase-2, resulting in morphological changes as part of tumour metastasis.12 Matrix metalloproteinase-2, which is involved in synaptic remodelling and synaptogenesis,13 is upregulated by Akt signalling, which is activated by the expression of NNMT in RCC cells.12 Akt, also known as protein kinase B, is a serine/threonine kinase that belongs to the cAMP-dependant protein kinase A/G/C superfamily and is at the centre of a myriad of cellular activities, including growth, proliferation, energy metabolism and migration.14, 15, 16 The Akt pathway is activated by PI3 kinases, which phosphorylates Akt on residues Ser-473 and Thr-308, triggering downstream effects, including inhibition of p53, reduced expression of the pro-apoptotic gene Bim and increased translation of anti-apoptotic proteins.14, 16 Akt and phosphorylated Akt (AktPi) are neuroprotective.17, 18, 19 Enhanced Akt expression is neuroprotective against the toxicity of 6-hydroxydopamine in PD models.15, 20 The abundance of AktPi is significantly reduced in the dopaminergic neurones of the substantia nigra in PD patients,21 and the neuroprotective effects of rasagiline are mediated via the activation of Akt signalling.22
Akt phosphorylation is activated by the ephrin B receptor (ephB),20, 23 whose ligand ephrin B2 (EFNB2) is induced alongside NNMT as a result of increased hedgehog signalling in pancreatic cancer cells.24 EFNB2 regulates transcellular communication via interaction with ephB3 and B4 receptors, tyrosine kinases present on the post-synaptic termini of adjacent target cells.25 In the brain, EFNB2/ephB receptor signalling is involved in regulating neuronal and axonal migration, synaptic formation, function and plasticity26, 27, 28, 29 via interaction with a number of pre- and post-synaptic targets.30 Activation of the phosphorylation of Akt by the ephB receptor gives rise to morphological and functional changes such as increased synaptic formation, regulation of neuronal plasticity29 and protection of SH-SY5Y cells against the toxicity of 6-hydroxydopamine.20
From the above, it can be seen that increased NNMT expression is a feature of rapidly dividing cancer cells and in neurones as a response to stressful states, such as PD. Therefore, we explored the effect of NNMT expression upon neuronal morphology and differentiation using our SH-SY5Y cell model of NNMT expression (S.NNMT.LP).11 In addition, we have used a second cell line, N27–rat mesencephalic dopaminergic neurones–to confirm our findings.
Results
NNMT expression increased neurite branching and the presynaptic marker synaptophysin
To investigate the effect of NNMT expression upon neurone morphology, we used the S.NNMT.LP cell line, produced as part of our ongoing studies by the stable transfection of SH-SY5Y with a plasmid encoding NNMT C-terminally fused to the V5 epitope.11 A single NNMT mRNA transcript and a single NNMT-V5 protein of the correct molecular weight were expressed solely in S.NNMT.LP cells (Supplementary Figures S1A and S1B). Cell death was significantly lower in S.NNMT.LP compared with SH-SY5Y cells (Supplementary Figure S1C).
NNMT expression has been shown to induce morphological changes in RCC cells, so we hypothesised that NNMT-V5 expression may have a similar effect upon SH-SY5Y morphology. Changes in SH-SY5Y morphology were determined using phase contrast and differential interference contrast (DIC) microscopy. DIC imaging allowed easier analysis of neurite branches compared with phase-contrast images. Under phase-contrast microscopy, SH-SY5Y cells appeared rounded and showed a basic neuronal morphology (Supplementary Figure S2, top panels), with a limited number of neurites, intercellular connections and neurite branching. By contrast, S.NNMT.LP cells appeared more elongated (Supplementary Figure S2B, bottom panels), with increases in the number of neurites per cell and the degree of branching. The number of intercellular connections also increased.
Quantification using image analysis demonstrated that neurite length was lower in S.NNMT.LP compared with that of SH-SY5Y cells (18% decrease, P=0.0288; Figures 1a and b). The number of neurites per cell was increased in S.NNMT.LP compared with the number in SH-SY5Y cells (11% increase, P<0.001; Figure 1b top right panel), and the number of branches per neurite of S.NNMT.LP was significantly higher than those of SH-SY5Y cells (71% increase, P=0.0164) (Figure 1b bottom left panel). In SH-SY5Y cells, 39.6% of neurites had no branching (Figure 1b bottom right panel), 28.7% had 1 branch, 20.8% had either 2 or 3 branches, and only 10.9% of neurites had ≥4 branches. By contrast, in S.NNMT.LP cells, only 19.2% of neurites had no branches, 19.7% had only one branch 41.5% had either 2 or 3 branches; and a further 19.6% of neurites had ≥4 branches. Thus neurite branching was increased significantly in S.NNMT.LP cells compared with the parental SH-SY5Y cells.
We next investigated whether S.NNMT.LP demonstrated an increase in the expression of the presynaptic marker synaptophysin.31 Synaptophysin expression was detected as a 38 kDa protein in both SH-SY5Y and S.NNMT.LP cell lines (Figure 1c left panel). Expression of synaptophysin was significantly increased in S.NNMT.LP compared with that seen in SH-SY5Y cells (Figure 1c right panel, 41.4% increase, P=0.004, n=4).
The effect of NNMT upon neurone morphology was also investigated using N27 cells. Substantia nigra dopaminergic neurones are derived from the mesencephalon,32 hence N27 cells closely mimic dopaminergic neurones of the substantia nigra. Wild-type N27 cells expressed no NNMT mRNA (Supplementary Figure S3). Transient transfection of N27 using the pNNMT.D plasmid11 resulted in robust NNMT-V5 expression (Figure 1d left panel). Synaptophysin expression was undetectable in mock-transfected N27 cells, whereas transient expression of NNMT-V5 resulted in robust synaptophysin expression. Mock-transfected N27 cells demonstrated a degree of neuronal morphology but with very few neurites and no interneuronal connections (Figure 1d right panel). N27 cells expressing recombinant NNMT-V5 had significantly more neuronal processes with the presence of a number of interneuronal connections (Figure 1d right panel). These results confirm that NNMT-V5 expression induced the formation of neurites and the expression of synaptophysin in dopaminergic mesencephalic neurones.
NNMT expression increased dopamine uptake and release
Next, we investigated whether dopamine uptake and release was increased by NNMT-V5 expression. Dopamine accumulation was significantly increased in S.NNMT.LP compared with SH-SY5Y cells (Figure 1e left panel, 4.8-fold increase, P=0.0154), with a corresponding increase in dopamine release (Figure 1e middle panel, 7.3-fold increase, P=0.0182). The percentage of the dopamine pool released was not significantly different in S.NNMT.LP compared with SH-SY5Y cells (Figure 1e right panel). Taken together, these results show that NNMT-V5 expression in SH-SY5Y cells changed cellular morphology and increased dopamine uptake and release.
The effects of NNMT expression were mediated via activation of EFNB2/Akt signalling
The next step was to elucidate the signalling pathway involved using S.NNMT.LP cells. The first candidate investigated was the EFNB2 signalling pathway. Both SH-SY5Y and S.NNMT.LP cell lines expressed a single EFNB2 mRNA transcript. EFNB2 protein expression was detected as two bands of approximately 49 and 28 kDa (Figure 2a upper panel), corresponding to the full-length and ectodomains of EFNB2, respectively.33, 34 EFNB2 mRNA expression was significantly increased in S.NNMT.LP compared with that in SH-SY5Y cells (189% increase, P=0.0037, n=4). Levels of both 49 and 28 kDa immunoreactive proteins was significantly higher in S.NNMT.LP cells (Figure 2a bottom panel, 564% increase, P= 0.0014 for 48 kDa protein, 612% increase, P=0.0182 for 28 kDa protein, n=3 for both).
We investigated whether there was increased Akt phosphorylation, as Akt is a downstream target of EFNB2. Both total Akt (AktT) and AktPi were detected as a single band of approximately 60 kDa in both SH-SY5Y and S.NNMT.LP cells, demonstrating robust expression of both (Figure 2b upper panel). AktT expression was not significantly different in S.NNMT.LP cells compared with that observed in SH-SY5Y (Figure 2b lower panel, 4.2% decrease, P=0.5179, n=3), whereas AktPi was increased in the presence of NNMT-V5 (35% increase, P=0.0044, n=3). Accordingly, the AktPi:AktT ratio increased in response to NNMT-V5 expression (41.3% increase, P=0.0248, n=3).
Next we demonstrated that EFNB2 was responsible for the increase in AktPi and synaptophysin expression we observed in S.NNMT.LP cells (Figure 3a). Silencing of EFNB2 expression in S.NNMT.LP cells (S.NNMT.LPEFNB2-) resulted in a significant decrease in EFNB2 compared with S.NNMT.LP cells transfected with scrambled siRNA (S.NNMT.LPWT; data not shown). Silencing of EFNB2 expression resulted in a significant decrease in AktPi (81.9% decrease, P=0.0004, n=4) and the AktPi:AktT ratio (77.7% decrease, P<0.0001, n=4), with no effect upon AktT (18.9% decrease, P=0.06, n=4). Silencing of EFNB2 expression significantly reduced synaptophysin expression (46.1%, P=0.0006, n=4). Silencing of EFNB2 expression resulted in a small yet significant reduction in the number of neurites per S.NNMT.LPEFNB2− cell compared with that in S.NNMT.LPWT (0.79±0.067 versus 0.7±0.06, 11% reduction, P<0.0001) (Figure 3b). Quantitative analysis of neurite length demonstrated that average neurite length in S.NNMT.LPEFNB2− cells was increased compared with that of S.NNMT.LPWT cells (35% increase, P=0.0005), with many neurites being hyper-elongated in S.NNMT.LPEFNB2− cells.
Finally, we investigated whether the phosphorylation of Akt was responsible for increased synaptophysin expression. Incubation of S.NNMT.LP cells with 50 μM LY294002 decreased AktPi (50% decrease, P=0.0034, n=4), the AktPi:AktT ratio (46.3% decrease, P=0.0052, n=4) and synaptophysin expression (56.3% decrease, P=0.001, n=4) (Figure 3c). These results demonstrate that the effects of NNMT-V5 expression upon SH-SY5Y cells were mediated via the sequential activation of the EFNB2 and Akt signalling pathways.
MeN replicated the effects of NNMT expression upon SH-SY5Y neurite branching
We next determined whether MeN, the metabolic product of NNMT, replicated the effects of NNMT-V5 upon SH-SY5Y morphology using DIC microscopy (Figure 4a). The amount of neurite branching appeared to be higher in SH-SY5Y cells incubated with MeN compared with untreated cells. The length of neuritic processes did not significantly increase with increasing MeN concentration (Figure 4b top left panel, 26.6±14.7 μm in untreated cells, compared with 30.1±20.6, 30.7±18.7 and 31.4±17.7 μm for 0.25, 0.5 and 1 mM MeN, respectively). The number of neuritic processes per cell incubated in 1 mM MeN increased by 10% compared with untreated cells (Figure 4b top right panel, 0.834±0.002 versus 0.918±0.016, P<0.001). The degree of neurite branching increased significantly in the presence of all concentrations of MeN (Figure 4b bottom left panel). In untreated cells, there were an average of 1.3±0.1 branches per neurite, which increased to 2.9±0.2 in cells incubated with 1 mM MeN, an increase of 124% (P<0.001). In all, 39% of neurite processes had no branching, with a further 26% only having one branch; only 5% of neurite processes had ≥4 branches (Figure 4b bottom right panel). This distribution shifted with increasing MeN concentration, with 19% of neuritic processes having ≥4 branches in cells cultured in the presence of both 0.25 mM and 0.5 mM MeN and 33% of neuritic processes having ≥4 branches in cells incubated in the presence of 1 mM MeN.
NNMT reduced cholinergic phenotype but did not induce terminal differentiation
In light of the increased dopamine uptake and release induced by NNMT-V5 expression, we investigated whether NNMT-V5 expression was involved in SH-SY5Y differentiation using western blotting analysis of various pan- and cell-specific neuronal markers using mouse brain homogenate as a positive control (Figure 5). The cholinergic marker Choline acetyltransferase (ChAT) was expressed as a ∼70 kDa protein in both SH-SY5Y and S.NNMT.LP cells and as a ∼72 kDa protein in mouse brain, which is in accord with published reports.35, 36 ChAT expression was significantly lower in S.NNMT.LP cells (66% reduction, P=0.0066, n=4). The serotonergic marker tryptophan hydroxylase was expressed in SH-SY5Y, S.NNMT.LP and mouse brain as a ∼56 kDa protein and was unchanged by the expression of NNMT-V5 (7.1% decrease, P=0.3515, n=4). The dopaminergic/noradrenergic marker tyrosine hydroxylase (TH) was expressed in mouse brain as a ∼56 kDa protein and was undetected in both SH-SY5Y and S.NNMT.LP cells. The post-mitotic marker neuronal nuclei/FOX-3 (NeuN) was expressed in SH-SY5Y, S.NNMT.LP and mouse brain as a double band of ∼40–45 kDa protein as previously described.37 NeuN expression was unchanged by the expression of NNMT-V5 (12.9% decrease, P=0.2934, n=4). Therefore, NNMT expression reduced cholinergic phenotype but did not induce dopaminergic/noradrenergic, serotonergic or terminal differentiation.
Discussion
In this study, we show that NNMT expression increased the number of neurites per cell, the number of branches per neurite, the expression of the presynaptic marker synaptophysin and the uptake and release of dopamine in SH-SY5Y stably expressing NNMT-V5 (S.NNMT.LP). The effects upon neurite formation and synaptophysin expression were also repeated in N27 cells transiently expressing NNMT-V5. These changes were shown to be brought about via the induction of the EFNB2 and Akt cell signalling pathways, in that the expression of NNMT was shown to activate these pathways, whereas blockage of the pathways using (1) siRNA gene silencing of EFNB2 and (2) inhibition of Akt phosphorylation using LY294002 abolished the effects of NNMT-V5 expression. We also showed that the effects of NNMT-V5 expression upon neurite branching were replicated by the addition of MeN.
Although SH-SY5Y cells are widely used in neurodegenerative disease research, their suitability for such studies is controversial.38 SH-SY5Y are a tumour-derived pan-neuronal cell line maintained in continuous culture, which require terminal differentiation in order to phenotypically and morphologically resemble true neurones. Using various differentiation protocols, a number of neuronal phenotypes can be produced.39, 40, 41 Although a tumour-derived cell line, it is apparent from their robust expression of synaptophysin and ability to accumulate and release dopamine that undifferentiated SH-SY5Y cells do possess neuronal characteristics, which make them useful for studies such as ours. SH-SY5Y cells do not express NNMT, a fact we exploited in studies on the effects of NNMT expression.11 Thus, the combination of SH-SY5Y and S.NNMT.LP cells is an ideal model for investigating the molecular pathways underlying the cellular effects of NNMT. We also confirmed key experimental results (changes in cellular morphology and synaptophysin expression) using N27 cells, an immortalised rat mesencephalic neuronal cell line which expresses TH.42 Although also a cell line maintained in continuous culture, N27 were produced by the immortalisation of dopaminergic neurones derived from embryonic day 12 rat mesencephalon using the SV40 large T antigen.43, 44 Such a paradigm allows us to negate the possibility that the morphological effects observed arose as a consequence of the tumourigenic nature of SH-SY5Y cells.
The most significant result of our study is that, in both SH-SY5Y and N27 cells, expression of NNMT induced changes in morphology via the sequential activation of the EFNB2 and Akt signalling pathways. NNMT did not induce terminal differentiation as evidenced by the lack of change in the expression of the post-mitotic marker NeuN and the continued replication of both S.NNMT.LP and transiently transfected N27 cells. Also, NNMT does not appear to have a major role in determining dopaminergic phenotypic fate, demonstrated by both the lack of change in TH expression and the dopaminergic phenotype of N27 cells, which do not express NNMT. The activation of the EFNB2 and Akt signalling pathways has been shown to induce morphological changes, such as neuronal and axonal migration;27, 29 thus the ability of NNMT to activate EFNB2 and Akt signalling elevates NNMT from historically being considered to be a component of Phase II metabolism to regulating fundamental cell signalling pathways involved in neuronal development and survival.
It should be noted that, due to the pan-neuronal nature of the cell lines used, the effects that we observe in this study may not be replicated in terminally differentiated, non-dividing neurones in vivo. However, if these results were to be replicated, they would provide further evidence that the increased NNMT expression that we have observed in PD patients2, 10 may not be part of the pathogenic process but instead may be a stress response. However, enhanced NNMT expression may be toxic in vivo in a manner that cannot be observed using our in vitro models. A small number of studies have suggested that MeN is toxic towards neurones, using supraphysiological concentrations of MeN,45, 46, 47 which are unlikely to be achieved even under conditions of high NNMT expression. It is also possible that NNMT may deleteriously affect pyridine nucleotide production, but although we have previously shown that NNMT expression reduced pyridine nucleotide synthesis, this had no deleterious effect upon SH-SY5Y cell survival.11 Finally, NNMT may potentially increase the production of methylated tetrahydroisoquinolines and β-carbolines, endogenously produced compounds which inhibit CxI;48 however, as yet there is no direct experimental evidence that NNMT is responsible for the production of such compounds.
Materials and Methods
Unless otherwise stated, all materials were obtained from Sigma-Aldrich (Poole, Dorset, UK) and were of the highest purity available. Male C57BL/6 mice were obtained from the Biological Services Unit, King’s College London, London, UK from which brain homogenate was prepared as previously described.2
Cell culture incubations
SH-SY5Y human neuroblastoma and S.NNMT.LP cells (SH-SY5Y stably expressing NNMT produced as part of our ongoing studies) were cultured as previously described.11 Recombinant NNMT (NNMT-V5) expression and reduced S.NNMT.LP cell death compared with SH-SY5Y were confirmed as previously described.11 For all experiments, SH-SY5Y cells at passage 19–22 and S.NNMT.LP cells at passage number 7–9 (which correlates approximately with passage 22–24 for SH-SY5Y) were used. In order to facilitate the investigation of the effect of NNMT upon cell morphology and differentiation, both SH-SY5Y and S.NNMT.LP cells were used in their undifferentiated state. N27 rat mesencephalic dopaminergic neurones were cultured in AQMedia (Sigma, Poole, UK) supplemented with 10% FBS, 2 mM glutamine and 100 U/ml penicillin/streptomycin.
Cell morphology analysis
SH-SY5Y and S.NNMT.LP cell morphology was quantitatively analysed by DIC microscopy at 37 °C using a Zeiss AxioPlan 2 microscope (Carl Zeiss, Welwyn Garden City, UK) with a × 40 objective lens, combined with image analysis involving three measures of cellular morphology: neurites per cell, neurite length, and the number of neurite branches. SH-SY5Y and S.NNMT.LP cells were incubated on poly-L-lysine-coated glass microscopy slides overnight, after which they were mounted in media under a coverslip. Image analysis was performed using Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA) on seven independent images for each cell line. The total number of cells counted was 184 for SH-SY5Y and 294 for S.NNMT.LP. Only neurites >15 μm in length were considered as true neuritic processes and as such counted. The number of neuritic processes per image was counted, normalised for the number of nuclei present in the image and expressed as neuritic processes per cell±S.E.M. The total number of neuritic processes counted was 132 for SH-SY5Y and 198 for S.NNMT.LP. The lengths of these neurites were measured and expressed as the average neuritic process length in μm±S.E.M. The number of branches of each neurite included in the above analyses was counted and expressed as number of branches per neurite±S.E.M. The population distribution of the number of neurite branches per neurite was also calculated and expressed as a percentage of neurites.
The effect of MeN upon SH-SY5Y cell morphology was also quantitatively assessed using DIC. Cells were incubated as above for 24 h in media supplemented with 0, 0.25, 0.5 and 1 mM MeN. Five unique images were analysed for each incubation condition with the following total number of cells per incubation condition counted: 184 (untreated), 143 (0.25 mM MeN), 183 (0.5 mM MeN), and 146 (1 mM MeN). The total number of neuritic processes counted per incubation condition were 132 (untreated), 120 (0.25 mM MeN), 127 (0.5 mM MeN), and 131 (1 mM MeN).
Transient expression of NNMT in N27 cells
N27 cells were seeded at a density of 75 000 cells/ml into the wells of a six-well plate and allowed to grow until approximately 75% confluent. Cells were transiently transfected using the pNNMT-D plasmid, which encodes NNMT C-terminally fused with the V5 epitope.11 After 48 h, recombinant NNMT-V5 expression was detected using western blotting. Cells were imaged under phase-contrast microscopy using a Canon D30 digital SLR camera mounted to an Axiovert C40 microscope (Zeiss).
[3H]-Dopamine accumulation and release
The uptake and subsequent accumulation of [3H]-dopamine by SH-SY5Y and S.NNMT.LP cells were measured using the method of Lam et al.49 Specific dopamine uptake by dopamine transporters was differentiated from non-specific dopamine uptake by incubating identical samples in Krebs–Hepes buffer supplemented with 10 μM nomifensine.50 After accumulation, the cells were washed thrice with Krebs/HEPES for 15 min each and placed directly in ice. Cells were lysed using phosphate-buffered saline supplemented with 1% (v/v) Triton X-100 for 20 min, after which the homogenate was transferred into microcentrifuge tubes and centrifuged briefly to remove particulate material. [3H]-Dopamine was measured in the samples by mixing the homogenate 1 : 3 with Ultima Gold XR scintillation cocktail and counted using scintillation spectroscopy (Beckman, High Wycombe, UK). Further samples were assayed for protein concentration, and [3H]-dopamine accumulation was calculated and expressed as nmoles dopamine/mg protein/min±S.D.
Dopamine release from cells was stimulated using 50 mM potassium as previously described.51 After stimulation for 5 min, the cells were placed immediately in ice. The stimulation buffer was transferred without delay into microcentrifuge tubes and centrifuged briefly to pellet any particulate material and [3H]-dopamine counts were measured as described above. Further samples were assayed for protein concentration and stimulated [3H]-dopamine release was calculated and expressed as nmoles dopamine released/mg protein/min±S.D. Additionally, the fraction of the total dopamine pool released was calculated and expressed as a percentage of total dopamine pool released±S.D.
Reverse transcriptase PCR detection of NNMT expression
mRNA was isolated from SH-SY5Y and N27 cells and expression of NNMT mRNA was assessed using RT-PCR as described previously.11
Quantitative PCR analysis of EFNB2 mRNA expression
The expression of EFNB2 mRNA was quantified in SH-SY5Y and S.NNMT.LP cells using real-time quantitative PCR as previously described,11 using mRNA primers and the appropriate Universal Probe Library probes as internal quantification probe (Roche, Burgess Hill, UK) as outlined in Table 1. The housekeeping genes β-actin and glyceraldehyde-3-phosphate dehydrogenase (Table 1) were used to normalise mRNA expression. Results were calculated using the ΔΔCt method and expressed as a percentage of expression compared with SH-SY5Y cells±S.D., with EFNB2 mRNA in SH-SY5Y cells assigned an expression level of 100%. The presence of single bands in each sample was subsequently confirmed using DNA gel electrophoresis.
Quantitative western blot analysis of protein expression
The expression levels of recombinant NNMT (NNMT-V5), EFNB2, synaptophysin, AktT protein, TH, tryptophan hydroxylase, ChAT, NeuN and AktPi were quantified using quantitative western blotting.11 Proteins were detected as outlined in Table 2, and proteins were visualised using electrochemiluminescent detection. To normalise for protein concentration, membranes were stripped using Restore Western Stripping Reagent (Fisher Scientific, Loughborough, UK) and reprobed for β-tubulin as outlined in Table 2. Images were digitally captured, band intensities were quantified using densitometric analysis using the GeneTools image analysis software (Syngene, Cambridge, UK) and normalised for β-tubulin expression. Protein expression was calculated and expressed as a percentage of the intensity observed in control cells±S.D. Synaptophysin and NNMT-V5 expression levels in N27 cells were not quantified. Additionally, Akt phosphorylation was calculated by dividing the AktPi by the AktT intensity to produce the AktPi:AktT ratio, which was subsequently expressed as a percentage of AktPi:AktT observed in control cells±S.D.
siRNA-mediated silencing of EFNB2 expression
EFNB2 expression was silenced in S.NNMT.LP using MISSION EFNB2 esiRNA (Invitrogen, Paisley, UK). S.NNMT.LP cells were plated at a density of 75 000 cells/ml into the wells of a six-well plate and allowed to settle overnight, at which point cells were approximately 50% confluent. Cells were subsequently transfected with 1 nM of either EFNB2 esiRNA or scrambled esiRNA for 72 h, after which EFNB2 silencing was confirmed using RT-PCR using the same primers outlined in Table 1. Synaptophysin, AktT and AktPi protein expression were assessed using quantitative western blotting. Neurite length and the number of neurites per cell were assessed using quantitative image analysis of five randomly chosen phase-contrast microscopic images as described above and expressed as average length in μm±S.E.M. The number of cells counted was 136 for scrambled esiRNA-treated and 135 for EFNB2 esiRNA-treated cells.
Inhibition of Akt phosphorylation using LY294002
S.NNMT.LP cells were seeded at a density of 75 000 cells/ml and allowed to grow until approximately 75% confluent. Cells were incubated for 60 min in the presence or absence of 50 μM LY294002, after which the cells were lysed and AktT, AktPi and synaptophysin expression were detected using western blotting.
Statistical analyses
All statistical analyses comprised comparison between SH-SY5Y and S.NNMT.LP using Student’s t-test with Welch correction. The exception was the comparison of the effect of MeN upon SH-SY5Y morphology, which comprised one-way ANOVA with Tukey’s post hoc comparisons. For all analyses, P<0.05 was taken as significant.
Abbreviations
- AktPi:
-
phosphorylated Akt
- AktT:
-
total Akt
- ChAT:
-
choline acetyltransferase
- CxI:
-
Complex I
- DIC:
-
differential interference contrast
- EFNB2:
-
ephrin B2
- ephB:
-
ephrin B receptor
- MeN:
-
1-methylnicotinamide
- NeuN:
-
neuronal nuclei/FOX-3
- NNMT:
-
nicotinamide N-methyltransferase
- PD:
-
Parkinson’s disease
- RCC:
-
renal clear cell carcinoma
- TH:
-
tyrosine hydroxylase
References
Aksoy S, Szumlanski CL, Weinshilboum RM . Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterisation. J Biol Chem 1994; 269: 14835–14840.
Parsons RB, Smith ML, Williams AC, Ramsden DB . Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain. J Neurol Exp Neurol 2002; 61: 111–124.
Kassem HS, Sangar V, Cowan R, Clarke N, Margison GP . A potential role of heat shock proteins and nicotinamide N-methyltransferase in predicting response to radiation in bladder cancer. Int J Cancer 2002; 101: 454–460.
Roessler M, Rollinger W, Palme S, Hagmann ML, Berndt P, Engel AM et al. Identification of nicotinamide N-methyltransferase as a novel serum tumour marker for colorectal cancer. Clin Cancer Res 2005; 11: 6550–6557.
Tomida M, Ohtake H, Yokota T, Kobayashi Y, Kurosumi M . Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cells. J Cancer Res Clin Oncol 2008; 134: 551–559.
Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009; 28: 20.
Emanuelli M, Santarelli A, Sartini D, Ciavarella D, Rossi V, Pozzi V et al. Nicotinamide N-methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. Histol Histopathol 2010; 25: 15–20.
Sternak M, Khomich TI, Jakubowski A, Szafarz M, Szczepański W, Białas M et al. Nicotinamide N-methyltransferase (NNMT) and 1-methylnicotinamide (MNA) in experimental hepatitis induced by concanavalin A in the mouse. Pharmacol Rep 2010; 62: 483–493.
Kim HC, Mofarrahi M, Vassilakopoulos T, Maltais F, Sigala I, Debigare R et al. Expression and functional significance of nicotinamide N-methyltransferase in skeletal muscle of patients with chronic obstructive pulmonary disease. Am J Respir Care Med 2010; 181: 797–805.
Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB . High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson’s disease. Neurosci Lett 2003; 342: 13–16.
Parsons RB, Aravindan S, Kadampeswaran A, Evans EA, Sandhu KK, Levy ER et al. The expression of nicotinamide N-methyltransferase increases ATP synthesis and protects SH-SY5Y human neuroblastoma cells against the toxicity of Complex I inhibitors. Biochem J 2011; 436: 145–155.
Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK et al. Nicotinamide N-methyltransferase induces cellular invasion though activating matrix metalloproteinase-2 expression in clear renal cell carcinoma cells. Carcinogenesis 2011; 32: 138–145.
Fredrich M, Illing RB . MMP-2 is involved in synaptic remodelling after cochlear lesion. Neuroreport 2010; 21: 324–327.
Song G, Ouyang G, Bao S . The activation of Akt/PKB signalling pathway and cell survival. J Cell Mol Med 2005; 9: 59–71.
Burke RE . Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signalling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther 2007; 114: 261–277.
Levy OA, Malagelada C, Greene LA . Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors and final steps. Apoptosis 2009; 14: 478–500.
Namikawa K, Honma M, Abe K, Takeda M, Mansur K, Obata T et al. Akt/protein kinase B prevents injury-induced motor neuron death and accelerates neuronal regeneration. J Neurosci 2000; 20: 2875–2886.
Du Y, Li X, Yang D, Zhang X, Chen S, Huang K et al. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp Biol Med (Maywood) 2008; 233: 881–890.
Timmons S, Coakley MF, Moloney AM, O’Niel C . Akt signal transduction dysfunction in Parkinson’s disease. Neurosci Lett 2009; 467: 30–35.
Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF et al. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 2009; 30: 127–135.
Malagelada C, Jin D, Greene LA . RTP-801 is induced in Parkinson’s disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci 2008; 28: 14363–14371.
Sagi Y, Mandel S, Amit T, Youdim MB . Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 2007; 25: 35–44.
Steinle JJ, Meininger CJ, Forough R, Wu G, Wu MH, Granger HJ . Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem 2002; 277: 43830–43835.
Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008; 57: 1420–1430.
Georgakopoulos A, Xu J, Xu C, Mauger G, Barthet G, Robakis NK . Presenilin1/gamma-secretase promotes the EphB2-induced phosphorylation of ephrinB2 by regulating phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding protein. FASEB J 2011; 25: 3594–3604.
Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW et al. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 2000; 103: 945–956.
Henkemeyer M, Itkis OS, Ngo M, Hickmott PW, Ethell IM . Multiple EphB receptor tyrosine kinases shape dendritic spines in the hippocampus. J Cell Biol 2003; 163: 1313–1326.
McClelland AC, Sheffler-Collins SI, Kayser MS, Dalva MB . Ephrin-B1 and ephrin-B2 mediate EphB-dependent presynaptic development via syntenin-1. Proc Natl Acad Sci USA 2009; 106: 20487–20492.
Chen Y, Fu WY, Ip JP, Ye T, Fu AK, Chao MV et al. Ankyrin repeat-rich membrane spanning protein (kidins220) is required for neurotrophin and ephrin receptor-dependent dendrite development. J Neurosci 2012; 32: 8263–8269.
Sloniowski S, Ethell IM . Looking forward to EphB signaling in synapses. Semin Cell Dev Bio 2012; 23: 75–82.
Perović M, Mladenović A, Rakić L, Ruzdijić S, Kanazir S . Increase of GAP-43 in the rat cerebellum following unilateral striatal 6-OHDA lesion. Synapse 2005; 56: 170–174.
Hayes L, Ralls S, Wang H, Ahn S . Duration of Shh signaling contributes to mDA neuron diversity. Dev Biol 2013; 374: 115–126.
Ran X, Qin H, Liu J, Fan JS, Shi J, Song J . NMR structure and dynamics of human ephrin-B2 ectodomain: the functionally critical C-D and G-H loops are highly dynamic in solution. Proteins 2008; 72: 1019–1029.
Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R . The significance of ephB4 and ephrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2008; 134: 985–991.
Ishii K, Oda Y, Ichikawa T, Deguchi T . Complementary DNAs for choline acetyltransferase from spinal cords of rat and mouse: nucleotide sequences, expression in mammalian cells, and in situ hybridization. Brain Res Mol Brain Res 1990; 7: 151–159.
Oda Y, Nakanishi I, Deguchi T . A complementary DNA for human choline acetyltransferase induces two forms of enzyme with different molecular weights in cultured cells. Brain Res Mol Brain Res 1992; 16: 287–294.
Kim KK, Adelstein RS, Kawamoto S . Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. J Biol Chem 2009; 284: 31052–31061.
Sarkanen JR, Nykky J, Siikanen J, Selinummi J, Ylikomi T, Jalonen TO . Cholesterol supports the retinoic acid-induced synaptic vesicle formation in differentiating human SH-SY5Y neuroblastoma cells. J Neurochem 2007; 102: 1941–1952.
Xie HR, Hu LS, Li GY . SH-SY5Y human neuroblastoma cell-line: in vitro cell model of dopaminergic neurons in Parkinson’s disease. Chin Med J (Engl) 2010; 123: 1086–1092.
Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Ceña V et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 2000; 75: 991–1003.
Agholme L, Lindström T, Kågedal K, Marcusson J, Hallbeck M . An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 2010; 20: 1069–1082.
Kanthasamy AG, Anantharam V, Zhang D, Latchoumycandane C, Jin H, Kaul S et al. A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCδ) protects against dopaminergic neuronal degeneration in Parkinson's disease models. Free Radic Biol Med 2006; 41: 1578–1589.
Zhou W, Bercury K, Cummiskey J, Luong N, Lebtin J, Freed CR . Phenylbutyrate up-regulates the DJ-1 protein and protects neurones in cell culture and in animal models of Parkinson disease. J Biol Chem 2011; 286: 14941–14951.
Adams FS, La Rosa FG, Kumar S, Edwards-Prasad J, Kentroti S, Vernadakis A et al. Characterisation and implantation of two neuronal cell-lines with dopaminergic properties. Neurochem Res 1996; 21: 619–627.
Fukushima T, Tawara T, Isobe A, Hojo N, Shiwaku K, Yamane Y . Radical formation site of cerebral Complex I and Parkinson’s disease. J Neurosci Res 1995; 42: 385–390.
Fukushima T, Kaetsu A, Lim H, Moriyama M . Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson’s disease. Exp Toxicol Pathol 2002; 53: 469–473.
Mori Y, Sugawara A, Tsuji M, Kakamu T, Tsuboi S, Kanda H et al. Toxic effects of nicotinamide methylation on mouse brain striatum neuronal cells and its relation to manganese. Environ. Health Prev Med 2012; 17: 371–376.
Williams AC, Ramsden DB . Autotoxicity, methylation and a road to the prevention of Parkinson's disease. J Clin Neurosci 2005; 12: 6–11.
Lam PM, Hainsworth AH, Smith GD, Owen DE, Davies J, Lambert DG . Activation of recombinant human TRPV1 receptors expressed in SH-SY5Y human neuroblastoma cells increases [Ca(2+)](i), initiates neurotransmitter release and promotes delayed cell death. J Neurochem 2007; 102: 801–811.
Jiang H, Jiang Q, Feng J . Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 2004; 279: 54380–54386.
Ault DT, Werling LL . SH-SY5Y cells as a model for sigma receptor regulation of potassium-stimulated dopamine release. Brain Res 2000; 877: 354–360.
Acknowledgements
This work was supported by Parkinson’s UK (grant number 0505).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Edited by A Verkhratsky
Supplementary Information accompanies this paper on Cell Death and Disease website
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
About this article
Cite this article
Thomas, M., Saldanha, M., Mistry, R. et al. Nicotinamide N-methyltransferase expression in SH-SY5Y neuroblastoma and N27 mesencephalic neurones induces changes in cell morphology via ephrin-B2 and Akt signalling. Cell Death Dis 4, e669 (2013). https://doi.org/10.1038/cddis.2013.200
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cddis.2013.200
Keywords
This article is cited by
-
High Expression of Nicotinamide N-Methyltransferase in Patients with Sporadic Alzheimer’s Disease
Molecular Neurobiology (2021)
-
Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization
Breast Cancer Research (2019)
-
The Protective Effects and the Involved Mechanisms of Tanshinone IIA on Sepsis-Induced Brain Damage in Mice
Inflammation (2019)
-
Role of Nicotinamide N-Methyltransferase in Dorsal Striatum in Cocaine Place Preference
Neuropsychopharmacology (2017)
-
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Oncogene (2017)